Lung Cancer News

CancerConnect lung cancer news, tips, and features provide breaking research stories, helpful tips, and inspiring features related to ovarian cancer. The unique daily cancer news service evaluates all aspects of lung cancer research and reports on the developments that are most important to cancer patients and healthcare providers, while the tips and features offer insight into all aspects of lung cancer treatment and survivorship.

Share

Lung Cancer News


Keytruda® Demonstrates Superior Survival Compared to Chemotherapy as First-Line Treatment for Advanced Non-Small Cell Lung Cancer (July 5, 2016)

Teatment with Keytruda® (pembrolizumab) for previously untreated advanced non-small cell lung cancer (NSCLC) whose tumors expressed high levels of PD-1 is superior to standard chemotherapy. Lung cancer... Continue Reading

First Targeted Therapy Shows Promise in Small Cell Lung Cancer (June 7, 2016)

Small cell lung cancer (SCLC) accounts for approximately 20–25% of all lung cancers. SCLC is an aggressive and fast-growing type of cancer that is very responsive to chemotherapy. However, although initial... Continue Reading

PD-1 Inhibitor Keytruda® Combined with Chemotherapy Promising in Lung Cancer Will be Evaluated in Larger Clinical Trials (June 6, 2016)

According to experts at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting in Chicago, new data evaluating Keytruda® (pembrolizumab) in combination with chemotherapy appears promising... Continue Reading

Two-Drug Immunotherapy Deemed Safe for Small Cell Lung Cancer Patients, Moffitt Study Shows (June 6, 2016)

Small cell lung cancer (SCLC) represents approximately 14 percent of all types of lung cancer. Many patients with SCLC respond to initial chemotherapy; however, they eventually relapse and develop progressive... Continue Reading

Another Study Confirms That Daily Aspirin Lowers Risk of Colorectal & Other GI Tract Cancers (May 9, 2016)

The regular use of aspirin significantly reduces the overall risk of cancer, especially colorectal and other gastrointestinal tract cancers, according to a study published in JAMA Oncology.1 The recent... Continue Reading

Xalkori® Approved for Lung Cancer with ROS-1 Gene Alterations (March 29, 2016)

The United States Food and Drug Administration (FDA) approved Xalkori (crizotinib) as treatment for patients with advanced non-small cell lung cancer (NSCLC) whose cancer has an alteration within the ROS-1... Continue Reading

Alecensa® Delays Cancer Progression Longer Than Xalkori® in Certain Lung Cancers (March 3, 2016)

Interim results from a large clinical trial demonstrated that the targeted agent Alecensa® (alectinib) delays the progression of cancer for a longer period of time than Xalkori® (crizotinib) among patients... Continue Reading

Lung Cancer Advances: Precision Medicine and Immunotherapy Make a Difference (March 1, 2016)

Precision medicine continues to impact the lives of lung cancer patients with research into genomics and genetics leading to unprecedented progress in improving outcomes. Tailored treatments have emerged... Continue Reading

Immune-Targeting Drug Combo Shows Promise for Non-Small Cell Lung Cancer Patients, Say Moffitt Cancer Center Researchers (February 22, 2016)

Lung cancer is the most common cause of cancer-related deaths in the United States resulting in more than 158,000 deaths each year. With a 5-year survival rate at only 18 percent, the development of new... Continue Reading

Important Step Toward Widespread Use Of Low-Dose Computed Tomography Lung Cancer Screening In The United States (January 29, 2016)

Excerpted from: Advances in Cancer Research And Treatment: 2015 Year In Review One strategy for reducing the death rate from lung cancer is to increase the rate of early detection so that cancers are found... Continue Reading

More Lung Cancer News

Latest Lung Cancer News By Stage


General

Keytruda® Demonstrates Superior Survival Compared to Chemotherapy as First-Line Treatment for Advanced Non-Small Cell Lung Cancer (July 5, 2016)

Teatment with Keytruda® (pembrolizumab) for previously untreated advanced non-small cell lung cancer (NSCLC) whose tumors expressed high levels of PD-1 is superior to standard chemotherapy. Lung cancer remains the leading cause of cancer-related deaths... Continue Reading

First Targeted Therapy Shows Promise in Small Cell Lung Cancer (June 7, 2016)

Small cell lung cancer (SCLC) accounts for approximately 20–25% of all lung cancers. SCLC is an aggressive and fast-growing type of cancer that is very responsive to chemotherapy. However, although initial anticancer responses to chemotherapy may be... Continue Reading

PD-1 Inhibitor Keytruda® Combined with Chemotherapy Promising in Lung Cancer Will be Evaluated in Larger Clinical Trials (June 6, 2016)

According to experts at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting in Chicago, new data evaluating Keytruda® (pembrolizumab) in combination with chemotherapy appears promising for the treatment of non-small cell lung cancer... Continue Reading

Two-Drug Immunotherapy Deemed Safe for Small Cell Lung Cancer Patients, Moffitt Study Shows (June 6, 2016)

Small cell lung cancer (SCLC) represents approximately 14 percent of all types of lung cancer. Many patients with SCLC respond to initial chemotherapy; however, they eventually relapse and develop progressive disease that has no effective treatment options.... Continue Reading

Xalkori® Approved for Lung Cancer with ROS-1 Gene Alterations (March 29, 2016)

The United States Food and Drug Administration (FDA) approved Xalkori (crizotinib) as treatment for patients with advanced non-small cell lung cancer (NSCLC) whose cancer has an alteration within the ROS-1 gene. Xalkori is already approved for the treatment... Continue Reading

More General

CancerConnect Cancer Commuity & Discussions


Cancer Types

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS